Form 4: Director David Grayzel Acquires Q32 Bio Stock Options

Director David Grayzel of Q32 Bio Inc. was granted stock options to acquire 9,810 shares of common stock.

Summary

• Director David S. Grayzel of Q32 Bio Inc. was granted stock options on June 12, 2026.
• The options are for 9,810 shares of common stock with an exercise price of $12.64 per share.
• These options are set to expire on June 11, 2036.
• The underlying shares will vest in full upon the earlier of June 12, 2027, or the Issuer's next annual meeting of stockholders, contingent on continued service.
• Grayzel disclaims beneficial ownership of these securities, except for any pecuniary interest, as proceeds from any sale will be transferred to Atlas Venture Life Science Advisors, LLC.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it represents a standard grant of stock options to a director with a disclaimer of beneficial ownership, which does not inherently signal positive or negative performance.

Positives

• Director granted stock options, indicating potential alignment of management interests with shareholder value.
• The grant of options suggests confidence in the company's future prospects by the compensation committee or board.

Negatives

• The reporting person, David S. Grayzel, disclaims beneficial ownership of the underlying shares, indicating the economic benefit may not directly accrue to him.
• The proceeds from any sale of shares acquired through these options will be transferred to Atlas Venture Life Science Advisors, LLC.

Risks

• The vesting of options is contingent on the Reporting Person's continued service, creating a potential retention risk if the individual departs.
• The disclaimer of beneficial ownership introduces complexity regarding who ultimately benefits from the potential appreciation of the underlying shares.

Future Outlook

The vesting schedule for the stock options suggests a forward-looking incentive tied to continued service and the company's annual meeting, implying a focus on long-term engagement and performance.

Management Comments

• The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

Industry Context

StockSavvy.ai notes that the granting of stock options to directors is a common practice in the biotechnology sector to align executive incentives with long-term company growth and shareholder value, especially for early-stage or growth-oriented companies like Q32 Bio Inc.

Related Party Transactions

• The reporting person, David S. Grayzel, is a director. The proceeds from the exercise and sale of shares underlying the options will be transferred to Atlas Venture Life Science Advisors, LLC, indicating a related party transaction or arrangement.

Stakeholder Impact

• Shareholders: The grant of options aligns director incentives with potential future stock price appreciation, but the disclaimer of beneficial ownership means the direct financial benefit may not accrue to the director personally.
• Employees: Standard compensation practice, unlikely to have direct impact.
• Creditors: No direct impact.
• Suppliers: No direct impact.

Next Steps

• The stock options will vest in full upon the earlier of June 12, 2027, or the Issuer's next annual meeting of stockholders, subject to continued service.
• Upon exercise, any proceeds from the sale of shares will be transferred to Atlas Venture Life Science Advisors, LLC.

Key Dates

Keywords

Form 4, SEC Filing, Stock Options, Insider Trading, Q32 Bio Inc., David Grayzel, Beneficial Ownership, Director Compensation, Equity Grant